	Takeda is represented by a distributor in Cyprus and provided indirect support to the in report mentioned entity													
	Disclosure Year: 2024								Date of Publication:	Date of Publication: 30-Jun-2025				
	Full Name	HCPs: City of Principal Practice HCOs: City where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL	Donations and Grants to	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)		Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)			TOTAL		
	(Art.1.01)	(Art.3)	(Schedule1)	(Art.3)	(Art.3)	HCOs (Art. 3.01.1.a)	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accomodation relevant to the contract		OPTIONAL	
l	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
S	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
皇	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					N/A	N/A						<u> </u>	
_	Number of Recipients in aggregate disclosure - Art. 3.02					N/A	N/A							
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A	N/A						N/A	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
	КҮПРІАКН АІМАТОЛОГІКН ЕТАІРЕІА	CYPRUS	Cyprus	CYPRUS			3,000.00						3,000.00	
COS	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
_	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02													
	Number of Recipients in aggregate disclosure - Art. 3.02													
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02												N/A	
		AGGREGATE DISCLOSURE												
% D S S D	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											0.00	3,000.00	